КЛИНИЧЕСКИЕ ПРОЯВЛЕНИЯ, ИММУНОПАТОГЕНЕЗ ДИФФУЗНОГО ТОКСИЧЕСКОГО ЗОБА
Ключевые слова:
Диффузный токсический зоб, клинические проявления, иммунопатогенезАннотация
Настоящий обзор литературы посвящен актуальной проблеме в области эндикринологии, как ДТЗ. Показаны основные клинические проявления ДТЗ связаные с избытком гормонов щитовидной железы, влияющие одновременно на несколько различных систем организма. Описана роль иммунологических механизмов, интерлейкинов в формировании заболевания.
Поражение сердечно-сосудистой системы — частое и серьезное осложнение диффузного токсического зоба (ДТЗ), нередко выступающее в клинической картине на первый план и определяющее течение и исход заболевания. Для обозначения этого поражения R. Kraus в 1899 г. ввел термин “тиреотоксическое сердце”, и в настоящее время под ним понимается симптомокомплекс нарушений деятельности сердечно-сосудистой системы, вызванных токсическим действием избытка тиреоидных гормонов (ТЕ) и характеризующихся развитием гиперфункции, гипертрофии, дистрофии, кардиосклероза и сердечной недостаточности (СН).
Библиографические ссылки
Akamizu T, Satoh T, Isozaki O, et al. Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid 2012;22:661-79
Antonelli A, Saracino A, Alberti B, et al. High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy. Acta Endocrinol 1992;126:13-23.
Antonelli A, Ferrari SM, Frascerra S, et al. Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine 2011;55:288-93.
Antonelli A, Ferrari SM, Corrado A, et al. Autoimmune thyroid disorders. Autoimmun Rev 2015;14:174-80
Abbas AK, Murphy KM, Sher A. Functional diversity of T lymphocytes. Nature. 1996;383:787–793
Boelaert K, Torlinska B, Holder RL, et al. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metabol 2010; 95:2715-26.
Brent GA. Clinical practice. Graves' disease. N Engl J Med 2008;358:2594-605
Burch HB, Cooper DS. Management of Graves’ disease: a review. JAMA, J Am Med Assoc 2015;314:2544e54.
Chang CC, Cheng CJ, Sung CC, et al. A 10-year analysis of thyrotoxic periodic paralysis in 135 patients: focus on symptomatology and precipitants. Eur J Endocrinol 2013;169:529-36
Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol 2001;55:283-303.;
Davies TF, Burch HB. Clinical features and diagnosis of Graves' orbitopathy (ophthalmopathy). 2019.
Diana T, Olivo PD, Kahaly GJ. Thyrotropin receptor blocking antibodies. Horm Metab Res 2018;50:853-62
Diana T, Krause J, Olivo PD, et al. Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease. Clin Exp Immunol 2017;189:304-9.
Dardalhon V, Korn T, Kuchroo VK, Anderson AC. Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun. 2008;31:252–256.
Davies TF, Martin A, Concepcion ES, et al. Evidence of limited variability of antigen receptors on intrathyroidal T cells in autoimmune thyroid disease. N Engl J Med. 1991;325:238–244.
Ferrari SM, Ruffilli I, Elia G, et al. Chemokines in hyperthyroidism. J Clin Transl Endocrinol 2019; 16:100196.
Ferrari SM, Fallahi P, Ruffilli I, et al. The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): review of the literature and report of a large series. Autoimmun Rev 2019;18:287-92.
Fallahi P, Ferrari SM, Ragusa F, et al. Th1 chemokines in autoimmune endocrine disorders. J Clin Endocrinol Metabol 2019. pii: dgz289. [Epub ahead of print].
Fisfalen ME, Palmer EM, Van Seventer GA, et al. Thyrotropinreceptor and thyroid peroxidase–specific T cell clones and their cytokine profile in autoimmune thyroid disease. J Clin Endocrinol Metab. 1997;82:3655–3663
Fisfalen ME, Palmer EM, Van Seventer GA, et al. Thyrotropinreceptor and thyroid peroxidase–specific T cell clones and their cytokine profile in autoimmune thyroid disease. J Clin Endocrinol Metab. 1997;82:3655–3663. 161.
Huppa JB, Davis MM. The interdisciplinary science of T-cell recognition. Adv Immunol. 2013;119:1–50.
Hirai N, Watanabe M, Inoue N, et al. Association of IL6 gene methylation in peripheral blood cells with the development and prognosis of autoimmune thyroid diseases. Autoimmunity 2019;52:251-5.
Imani D, Rezaei R, Razi B, et al. Association between IL6-174 G/C polymorphism and graves' disease: a systematic review and meta-analysis. Acta Med Iran 2017;55:665-71.
Kotwal A, Stan M. Thyrotropin receptor antibodies-an overview. Ophthalmic Plast Reconstr Surg 2018;34:S20e7.
Kahaly GJ, Diana T, Kanitz M, et al. Prospective trial of functional thyrotropin receptor antibodies in graves' disease. J Clin Endocrinol Metabol 2019. pii: dgz292. [Epub ahead of print].
Kronenberg M, Rudensky A. Regulation of immunity by selfreactive T cells. Nature. 2005;435:598–604. 158.
Li Y,Wang Z, Yu T, et al. Increased expression of IL-37 in patients with Graves' disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells. PloS One 2014;9:107183.
McLachlan SM, Rapoport B. Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev 2014; 35:59-105
Menconi F, Marcocci C, Marin_o M. Diagnosis and classification of Graves' disease. Autoimmun Rev 2014;13:398-402
MacFarland SP, Bauer AJ, Adzick NS, et al. Disease burden and outcome in children and young adults with concurrent Graves disease and differentiated thyroid carcinoma. J Clin Endocrinol Metabol 2018;103:2918-25
Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves’ disease. Immunol Res. 2012;54: 191–203.
Martin A, Davies TF. T cells and human autoimmune thyroid disease: Emerging data show lack of need to invoke suppressor T-cell problems. Thyroid. 1992;2:247–261
Mao C, Wang S, Xiao Y, et al. Impairment of regulatory capacity of CD4+CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves’ disease. J Immunol. 2011;186:4734–4743.
McIntosh RS, Watson PF, Pickerill AP, et al. No restriction of intrathyroidal T cell receptor V alpha families in the thyroid of Graves’ disease. Clin Exp Immunol. 1993;91:147–152.
Nakashima M, Kong YM, Davies TF. The role of T cells expressing TcR V beta 13 in autoimmune thyroiditis induced by transfer of mouse thyroglobulin-activated lymphocytes: Identification of two common CDR3 motifs. Clin Immunol Immunopathol. 1996; 80:204–210.
Perricone C, Versini M, Ben-Ami D, et al. Smoke and autoimmunity: the fire behind the disease. Autoimmun Rev 2016;15: 354e74.
Pan D, Shin YH, Gopalakrishnan G, Hennessey J, De Groot LJ. Regulatory T cells in Graves’ disease. Clin Endocrinol (Oxf). 2009; 71:587–593.
Qi Y, Li X, Zhang Q, et al. Increased chemokine (C-C motif) ligand 21 expression and its correlation with osteopontin in Graves' disease. Endocrine 2015;50:123-9.
Romagnani S. The Th1/Th2 paradigm and allergic disorders. Allergy 1998;53:12-5.
Rapoport B, McLachlan SM. Graves' hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease. J Clin Endocrinol Metabol 2014;99:4060-1.
Rapoport B, McLachlan SM. Reflections on thyroid autoimmunity: a personal overview from the past into the future.Horm Metab Res 2018;50:840-52.
Romagnani S. Regulation of the T cell response. Clin Exp Allergy. 2006;11:1357–1366.
Selmer C, Olesen JB, Hansen ML, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ: Br Med J/Br Med Assoc 2012;345:7895.6.
Smith TJ, Hegedüs L. Graves' disease. N Engl J Med 2016;375:1552-65.
Spinelli C, Bertocchini A, Antonelli A, et al. Surgical therapy of the thyroid papillary carcinoma in children: experience with 56 patients < or ¼16 years old. J Pediatr Surg 2004;39:1500-5.
Smith TJ. Is IGF-I receptor a target for autoantibody generation in Graves’ disease? J Clin Endocrinol Metab. 2013;98:515–518.
Tandon N, Freeman MA, Weetman AP. T cell response to synthetic TSH receptor peptides in Graves’ disease. Clin Exp Immunol. 1992;89:468–473.
Tu Y, Fan G, Zeng T, et al. Association of TNF-a promoter polymorphism and Graves' disease: an updated systematic review and meta-analysis. Biosci Rep 2018;38.
Vaidya B, Pearce SH. Diagnosis and management of thyrotoxicosis. BMJ: Br Med J/Br Med Assoc 2014;349:g5128.
Wemeau JL, Klein M, Sadoul JL, et al. Graves' disease: introduction, epidemiology, endogenous and environmental pathogenic factors. Ann Endocrinol 2018;79:599-607.
Watson PF, Pickerill AP, Davies R, Weetman AP. Analysis of cytokine gene expression in Graves’ disease and multinodular goiter. J Clin Endocrinol Metab. 1994;79:355–360.
